Takeda Pharmaceutical Company’s Ovid Therapeutics OVID Stock Holding History

Takeda Pharmaceutical Company’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$9.79M	Hold	7,531,996	–	–	59.82%	1
2025 Q2	$2.49M	Hold	7,531,996	–	–	12.71%	2
2025 Q1	$2.35M	Hold	7,531,996	–	–	14.51%	2
2024 Q4	$7.01M	Hold	7,531,996	–	–	26.4%	2
2024 Q3	$8.89M	Hold	7,531,996	–	–	23.42%	3
2024 Q2	$5.79M	Hold	7,531,996	–	–	2.49%	5
2024 Q1	$23M	Hold	7,531,996	–	–	7.95%	4
2023 Q4	$24.3M	Buy	+7,531,996	New	+$25.7M	7.41%	4

Other funds holding OVID

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Takeda Pharmaceutical Company's OVID Position: Q3 2025 in Review

Takeda Pharmaceutical Company held its Ovid Therapeutics (OVID) position steady in Q3 2025 at 7,531,996 shares worth $9.79M. The position accounts for 59.82% of the portfolio, ranked #1.

Takeda Pharmaceutical Company first reported a position in OVID in Q4 2023 and has held it in 8 quarters since. The position peaked at $24.3M in Q4 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Takeda Pharmaceutical Company held 7,531,996 shares of Ovid Therapeutics worth $9.79M as of Q3 2025.
Takeda Pharmaceutical Company left its Ovid Therapeutics share count unchanged in Q3 2025.
Ovid Therapeutics made up 59.82% of Takeda Pharmaceutical Company's portfolio in Q3 2025, its #1 holding.
Takeda Pharmaceutical Company first reported a position in Ovid Therapeutics in Q4 2023 and has held it in 8 quarters since.
Takeda Pharmaceutical Company's Ovid Therapeutics position peaked at $24.3M in Q4 2023.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.